These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 19443433)

  • 1. Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study.
    Andersen SS; Hansen ML; Gislason GH; Schramm TK; Folke F; Fosbøl E; Abildstrøm SZ; Madsen M; Køber L; Torp-Pedersen C
    Europace; 2009 Jul; 11(7):886-91. PubMed ID: 19443433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial.
    Gulizia M; Mangiameli S; Orazi S; Chiarandà G; Piccione G; Di Giovanni N; Colletti A; Pensabene O; Lisi F; Vasquez L; Grammatico A; Boriani G;
    Am Heart J; 2008 Jan; 155(1):100-7, 107.e1. PubMed ID: 18082498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis.
    Kim MH; Smith PJ; Jhaveri M; Lin J; Klingman D
    Clin Ther; 2011 Nov; 33(11):1668-1681.e1. PubMed ID: 22108302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide.
    Zarembski DG; Nolan PE; Slack MK; Caruso AC
    Arch Intern Med; 1995 Sep; 155(17):1885-91. PubMed ID: 7677555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations to antiarrhythmic drug use in patients with atrial fibrillation.
    Humphries KH; Kerr CR; Steinbuch M; Dorian P;
    CMAJ; 2004 Sep; 171(7):741-5. PubMed ID: 15451836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs.
    Friberg L
    Am Heart J; 2018 Nov; 205():118-127. PubMed ID: 30236980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Freudenberger RS; Hellkamp AS; Halperin JL; Poole J; Anderson J; Johnson G; Mark DB; Lee KL; Bardy GH;
    Circulation; 2007 May; 115(20):2637-41. PubMed ID: 17485579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial.
    Gulizia M; Mangiameli S; Chiarandà G; Spadola V; Di Giovanni N; Colletti A; Bulla V; Circo A; Pensabene O; Vasquez L; Vaccaro I; Grammatico A;
    Europace; 2006 Apr; 8(4):302-5. PubMed ID: 16627459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers.
    Hansen ML; Gadsbøll N; Gislason GH; Abildstrom SZ; Schramm TK; Folke F; Friberg J; Sørensen R; Rasmussen S; Poulsen HE; Køber L; Madsen M; Torp-Pedersen C
    Europace; 2008 Apr; 10(4):395-402. PubMed ID: 18258807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
    Hagens VE; Rienstra M; Van Veldhuisen DJ; Crijns HJ; Van Gelder IC
    Am J Cardiol; 2006 Oct; 98(7):929-32. PubMed ID: 16996876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality after catheter ablation for atrial fibrillation compared with antiarrhythmic drug therapy. A meta-analysis of randomized trials.
    Dagres N; Varounis C; Flevari P; Piorkowski C; Bode K; Rallidis LS; Tsougos E; Leftheriotis D; Sommer P; Hindricks G; Kremastinos DT
    Am Heart J; 2009 Jul; 158(1):15-20. PubMed ID: 19540387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events.
    Almroth H; Andersson T; Fengsrud E; Friberg L; Linde P; Rosenqvist M; Englund A
    J Intern Med; 2011 Sep; 270(3):281-90. PubMed ID: 21635583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation.
    Kilborn MJ; Rathore SS; Gersh BJ; Oetgen WJ; Solomon AJ
    Am Heart J; 2002 Dec; 144(6):1095-101. PubMed ID: 12486436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
    Connolly SJ; Crijns HJ; Torp-Pedersen C; van Eickels M; Gaudin C; Page RL; Hohnloser SH;
    Circulation; 2009 Sep; 120(13):1174-80. PubMed ID: 19752319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.
    Allen LaPointe NM; Dai D; Thomas L; Piccini JP; Peterson ED; Al-Khatib SM
    Am J Cardiol; 2015 Feb; 115(3):316-22. PubMed ID: 25491240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned.
    Vijayalakshmi K; Whittaker VJ; Sutton A; Campbell P; Wright RA; Hall JA; Harcombe AA; Linker NJ; Stewart MJ; Davies A; de Belder MA
    Am Heart J; 2006 Apr; 151(4):863.e1-6. PubMed ID: 16569550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Outpatient treatment of recurrent atrial fibrillation with the "pill-in-the-pocket" approach: practical aspects].
    Alboni P; Botto GL; Baldi N
    Ital Heart J Suppl; 2005 Jun; 6(6):335-40. PubMed ID: 16013424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65.
    D'Angelo RN; Rahman M; Khanna R; Yeh RW; Goldstein L; Yadalam S; Kalsekar I; Tung P; Zimetbaum PJ
    J Cardiovasc Electrophysiol; 2021 Jun; 32(6):1529-1537. PubMed ID: 33760297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs.
    Allen LaPointe NM; Dai D; Thomas L; Piccini JP; Peterson ED; Al-Khatib SM
    Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):292-300. PubMed ID: 25829248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.